The University of Miami School of Medicine received a $674,440 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) to conduct research aimed at differentiating benign and malignant multiple myeloma precursor conditions. The study will leverage single-cell whole genome sequencing and RNA analysis to comprehensively define the clinical impact of key genomic and immune events that distinguish progressive from stable myeloma precursor states. This research seeks to identify early molecular indicators that can enable strategies for the early prevention and intervention of multiple myeloma, a prevalent and deadly hematological cancer. The project will run from February 2025 through January 2030, building on the university's previous work in using whole genome sequencing to identify critical myeloma-defining genomic events.
Generated 3/4/25, 8:16 AM